TP53-mut CLL contraindicates chemoimmunotherapy (FCR/BR). BTKi (acalabrutinib, zanubrutin...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-TP53-MUT-CLL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-CLL |
| Sources | SRC-CIVIC SRC-ESMO-CLL-2024 SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-TP53-MUTATION |
|---|---|
| Variant | any pathogenic mutation OR del(17p) |
| Disease | DIS-CLL |
| ESCAT tier | IIIA |
| Recommended combinations | acalabrutinib monotherapy, zanubrutinib monotherapy, venetoclax + obinutuzumab (CLL14), BTKi + venetoclax (CAPTIVATE / GLOW) |
| Evidence summary | TP53-mut CLL contraindicates chemoimmunotherapy (FCR/BR). BTKi (acalabrutinib, zanubrutinib, ibrutinib) or BCL2i (venetoclax + obinutuzumab; CLL14) preferred. Some guidelines favor venetoclax-based fixed-duration over continuous BTKi for high-risk; data evolving. |
Notes
ESCAT IIIA. Gene-level cell — biallelic vs monoallelic distinction matters in MDS/AML (biallelic = TP53-multihit per IPSS-M / ICC 2022, far worse). Per-hotspot cells provided for the most common variants.
Used By
No reverse references found in the YAML corpus.